Cure Alzheimer’s Fund Strengthens Leadership with New Board Appointments

The Cure Alzheimer’s Fund has announced the addition of Christine Villas-Boas and Brittany Bowlen to its Board of Directors, marking a significant step in its mission to combat Alzheimer’s disease. This move underscores the organization's commitment to leveraging diverse expertise and passion to advance research efforts aimed at finding a cure for this debilitating condition.

Christine Villas-Boas, with her extensive background in finance and philanthropy, and Brittany Bowlen, known for her strategic leadership in consulting and professional sports, bring valuable perspectives to the board. Their appointments are expected to bolster the fund's initiatives in funding groundbreaking research, with the ultimate goal of preventing, slowing, or reversing Alzheimer’s disease.

The inclusion of Villas-Boas and Bowlen is particularly noteworthy given their personal and professional dedication to making a difference in the fight against Alzheimer’s. Villas-Boas’s involvement is inspired by her family’s experience with the disease, while Bowlen’s commitment to community impact aligns with the fund’s objectives. Their leadership is anticipated to enhance the organization’s strategic direction and its ability to support critical research projects.

Since its inception in 2004, Cure Alzheimer’s Fund has been at the forefront of Alzheimer’s research, contributing over $232 million to more than 300 leading researchers worldwide. The fund’s efforts have led to significant breakthroughs in understanding the disease, and the addition of new board members signals a continued push towards innovative solutions. With Alzheimer’s disease affecting millions globally, the fund’s work remains crucial in addressing one of the most pressing health challenges of our time.